Sarah Farukhi Ahmed1,2, Anand Bhatt3,4, Mason Schmutz3,4, Sameh Mosaed3,4. 1. Gavin Herbert Eye Institute, University of California-Irvine, 850 Health Sciences Road, Irvine, CA, 92697-4375, USA. sfarukhi@gmail.com. 2. Irvine School of Medicine, University of California, Irvine, CA, 92697, USA. sfarukhi@gmail.com. 3. Gavin Herbert Eye Institute, University of California-Irvine, 850 Health Sciences Road, Irvine, CA, 92697-4375, USA. 4. Irvine School of Medicine, University of California, Irvine, CA, 92697, USA.
Abstract
PURPOSE: To compare the efficacy of ab-interno trabeculotomy with Trabectome® in mild glaucoma versus moderate/severe glaucoma along the spectrum of glaucoma disease severity. METHODS: Subjects with at least 12 months follow-up were separated into two groups based on glaucoma severity. Severity was determined based on optic nerve cup-to-disc ratio and/or automated visual field data, with cup-to-disc ratio < 0.7 and/or visual field mean deviation ≤ 6.0 dB used to define the mild group (n = 1127), and cup-to-disc ratio > 0.7 and/or visual field mean deviation > 6.0 dB used to define the moderate/severe group (n = 1071). These groups were further subdivided into patients undergoing Trabectome with cataract surgery or Trabectome alone. Mean IOP reduction, medication usage, and success rates were compared between the two groups. Success was defined as IOP reduction of 20% or more from pre-operative IOP and IOP less than 21 mmHg with no secondary surgery throughout the follow-up period. RESULTS: The mean post-operative IOP and success rates were similar between the groups. IOP reduction for the mild group was 26% (from pre-op IOP of 24 to 16.1 mmHg) and for the moderate/severe group was 24% (from pre-op IOP of 22.6 to 15.7 mmHg) at 12 Months. The overall rate of success at 12 months for the mild group was 86% and for the moderate/severe group was 83%. CONCLUSION: Trabectome surgery maintains efficacy across the spectrum of glaucoma disease severity. This particular minimally invasive glaucoma surgery procedure can be an excellent choice for subjects with moderate/advanced glaucoma as well as for early glaucoma with or without cataract surgery and is applicable to a broad patient population.
PURPOSE: To compare the efficacy of ab-interno trabeculotomy with Trabectome® in mild glaucoma versus moderate/severe glaucoma along the spectrum of glaucoma disease severity. METHODS: Subjects with at least 12 months follow-up were separated into two groups based on glaucoma severity. Severity was determined based on optic nerve cup-to-disc ratio and/or automated visual field data, with cup-to-disc ratio < 0.7 and/or visual field mean deviation ≤ 6.0 dB used to define the mild group (n = 1127), and cup-to-disc ratio > 0.7 and/or visual field mean deviation > 6.0 dB used to define the moderate/severe group (n = 1071). These groups were further subdivided into patients undergoing Trabectome with cataract surgery or Trabectome alone. Mean IOP reduction, medication usage, and success rates were compared between the two groups. Success was defined as IOP reduction of 20% or more from pre-operative IOP and IOP less than 21 mmHg with no secondary surgery throughout the follow-up period. RESULTS: The mean post-operative IOP and success rates were similar between the groups. IOP reduction for the mild group was 26% (from pre-op IOP of 24 to 16.1 mmHg) and for the moderate/severe group was 24% (from pre-op IOP of 22.6 to 15.7 mmHg) at 12 Months. The overall rate of success at 12 months for the mild group was 86% and for the moderate/severe group was 83%. CONCLUSION: Trabectome surgery maintains efficacy across the spectrum of glaucoma disease severity. This particular minimally invasive glaucoma surgery procedure can be an excellent choice for subjects with moderate/advanced glaucoma as well as for early glaucoma with or without cataract surgery and is applicable to a broad patient population.
Authors: Philip Enders; Friederike Schaub; Werner Adler; Roman Nikoluk; Manuel M Hermann; Ludwig M Heindl Journal: Br J Ophthalmol Date: 2016-07-19 Impact factor: 4.638
Authors: Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz Journal: Am J Ophthalmol Date: 2006-09-01 Impact factor: 5.258
Authors: David S Friedman; Henry D Jampel; Lisa H Lubomski; John H Kempen; Harry Quigley; Nathan Congdon; Hani Levkovitch-Verbin; Karen A Robinson; Eric B Bass Journal: Ophthalmology Date: 2002-10 Impact factor: 12.079
Authors: Adam R Bleeker; William R Litchfield; Mitch J Ibach; Michael D Greenwood; Deborah Ristvedt; John P Berdahl; Daniel C Terveen Journal: Clin Ophthalmol Date: 2022-07-21
Authors: D Kiessling; C Rennings; M Hild; A Lappas; T S Dietlein; G F Roessler; Randolf Alexander Widder Journal: Int Ophthalmol Date: 2021-08-07 Impact factor: 2.031